Breaking News

Argentina Didn't Reach an Agreement With Holdouts: Mediator
Tweet TWEET

Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013

 Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and
                     Host Conference Call on May 8, 2013

PR Newswire

Point Richmond, Calif., May 1, 2013

Point Richmond, Calif., May 1, 2013 /PRNewswire/ --Transcept Pharmaceuticals,
Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the
development and commercialization of proprietary products that address
important therapeutic needs in the field of neuroscience, today announced that
the company will host a conference call on Wednesday, May 8, 2013, at 4:30
p.m. Eastern Time to discuss its first quarter 2013 financial results. The
conference call will follow the release of the Transcept first quarter 2013
financial results after the close of market that day.

Conference Call Information
  Date: Wednesday, May 8, 2013
  Time: 4:30 p.m. ET
  Dial-in (U.S.): (877) 638-4558
  Dial-in (International): (914) 495-8537

A simultaneous webcast of the conference call will be available on the
Investors section of the Transcept website at www.transcept.com. A replay of
this webcast will be available on the website shortly after the conclusion of
the call and will be available through June 30, 2013.

About Transcept

Transcept Pharmaceuticals, Inc.is a specialty pharmaceutical company focused
on the development and commercialization of proprietary products that address
important therapeutic needs in the field of neuroscience. Intermezzo®
(zolpidem tartrate) sublingual tablet C-IV is the firstFDAapproved Transcept
product.PurduePharma holds commercialization and development rights for
Intermezzo in the United States. For further information about Transcept,
please visit www.transcept.com. For information about Intermezzo, please visit
www.IntermezzoRx.com.

Contact:
Transcept Pharmaceuticals, Inc.
Leone Patterson
Vice President and Chief Financial Officer
(510) 215-3512
lpatterson@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.

Website: http://www.transcept.com